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ABSTRACT 
Objectives: Erythrinine is a new ring-C-oxygenated Erythrina 
Methods: Quantitative structure-affinity relationship approach has been employed to determine the antismoking activity of Erythrinine and its 
analogues. Multiple molecular docking analyses was carried out using Auto dock 4.2 to determine the inhibitory constants of designed compounds. 
Multiple linear regression analyses using SPSS 17.0 were carried out to build quantitative structure-affinity relationship model. Computation of 
descriptors was done using Molecular Operating Environment. All molecular visualizations were done using Pymol.  
alkaloid from plant sources Erythrina Indica. The aim of this study is to investigate the 
smoking cessation activity of Erythrinine and its analogues using in silico computational approach. 
Results: The inhibitory constants of Erythrinine and Cytisine were found to be 5.95 and 30.23µM with negative binding energies of 7.13 and 
6.17kcal/Mol respectively. A quantitative structure-affinity relationship model was built with a correlation coefficient of 0.96. Compound 12, 11, 8 
and 7 were found to be highly active with inhibitory constants in the range of nanomolar concentrations. 
Conclusion: A quantitative structure-affinity relationship model with a strong correlation coefficient of 0.96 endorses that Erythrinine is having a 
strong affinity with α4β2 nACh receptors as Cytisine. Hence, the comparative study concluded that Erythrinine may use as an antismoking agent. 
Keywords: Erythrinine, Cytisine, Docking studies and smoking session. 
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INTRODUCTION 
Tobacco use is the single most important preventable health risk 
with an annual death of 4, 80,000 across the globe. Besides affecting 
various systems and causing diverse diseases such as malignancy, 
chronic obstructive pulmonary disease, coronary artery disease, 
stroke, peripheral vascular disease, and peptic ulcer, using tobacco 
with and without smoke remain the major cause of mortality [1]. 
Thus pharmacological and non-pharmacological modalities of 
smoking cessation play important roles in both increasing the life 
expectancy and increasing the health-related quality of life [2]. The 
current existing options for tobacco smoking cessation are limited. 
The FDA has approved nicotine replacement preparations such as 
nicotine gum, transdermal nicotine patches, nicotine nasal spray, 
nicotine inhaler and sustained release bupropion hydrochloride as 
first line agents for smoking cessation therapy. The prescription 
medications clonidine and nortriptyline hydrochloride are used as 
second-line agents. However, lack of FDA approval for smoking 
cessation and associated potential adverse effects limit the use of 
these agents for smoking cessation therapy [3].  
A common feature is the sparse knowledge of their pharmacology, in 
part due to a lack of selective receptor subtype ligands. The 
discovery of more selective nACh receptor agonists and antagonists 
is a prerequisite for an adequate understanding of CNS nicotinic 
function and for the development of useful agents potentially useful 
in the management of a broad range of mental conditions [11]. 
Pharmacological treatments such as nicotine-replacement therapy 
have been shown to help smokers stop smoking. Using a medication 
that does not contain nicotine, such as antidepressant have several 
reasons. Smokers are more likely to have a history of major 
depression than nonsmokers [4, 5]. Nicotine may act as an 
antidepressant in some smokers. [6, 7] the development of a 
depressed affect or depression after smoking cessation may lead to 
relapse. [8-10] hence a constant need for safer and effective novel 
molecules for smoking cessation therapy exists. Cytisine (cy) is an 
alkaloid with a strongly restricted conformation and well-
established nicotinic agonist pharmacology, exhibiting low 
nanomolar affinity at α4β2 nACh receptors and low micromolar 
affinity at the α7 subtype, which has been used as a template to infer 
active conformations of flexible nicotinic drugs [12]. In the human 
body, Cytisine plays the role of nicotine substitution substance, and 
reduces the period of the interaction of the received nicotine with 
relevant nicotine receptors, i.e. the specific substance Cytisine 
"substitutes" nicotine, acting on the same receptors, thus preventing 
the appearance of abstinence syndrome. This results in a gradual 
reduction and suspension of the psychic and physical dependency to 
nicotine in smokers. Cytisine possesses a structure and mechanism 
of action that are similar to those of nicotine, but it has much lower 
toxicity. Cytisine manifests one of the best results to date for the 
group of preparations, intended for tobacco smoking therapy. 
Cytisus laborinum L the source plant aka Golder Rain acacia. It is very 
well tolerated, and when applied in therapeutic doses, allows a 
gradual giving up of smoking without any side effects. Erythrinine, a 
new ring-C-oxygenated Erythrina 
The alkaloidal components of eight Erythrina plants (Leguminosae), 
E. arborescence Roxb., E. orientalis (L.) Murr, E. crysta-galli Linn, E. 
crysta-galli (L.) cv. Maruba Deiko H. Murata, E. x bidwilli Lindl, E. 
poeppigiana (Walp) O. F. Cook, E. glauca Willd, and E. indica L., which 
is having a similar structure of the Cytisine. [12, 13] Computer-aided 
structure-based drug design, molecular docking is frequently used to 
predict the putative geometry of a protein-ligand complex. The 
success of this computational methodology can be rapidly verified 
by parallel crystallography efforts. In addition, docking is often used 
in conjunction with scoring functions to predict binding affinities of 
ligands in virtual screening experiments and in studying structure-
activity relationships to prioritize synthesis of the new compound 
[14-16]. The aim of the study is to design to be simplified analogues 
of Aromatic Erythrinine with the aim of obtaining subtype-selective 
antagonists for the nAChRs and thereby probe the potential of using 
these natural products as scaffolds for further ligand optimization. 
Erythrinine have been investigated for the nicotinic agonist 
pharmacology, exhibiting low nanomolar affinity at α4β2 nACh 
receptors using the computer-aided structure-based drug design. 
Accuracy and precision of the Erythrinine was compared with the 
alkaloid,  
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Cytisine and finalized by evaluating the pharmacological properties 
of the initial lead compound at monoamine transporters and 
investigate to use in possible smoking cession-agent. 
MATERIALS AND METHODS  
Retrieval of crystal structure of human nicotinic acetylcholinergic 
receptor (nAchR) 
The three-dimensional crystal structure of human nAchR was 
retrieved from the 3D repository for macromolecules, the protein 
data bank (PDB id: 4UXU). The primary structure of the retrieved 3D 
macromolecule was cross-validated with its FASTA sequence from 
the PubMed protein database (ID: NP_001243502.1). 
Validation of protein confirmation and stability 
The dihedral angles phi and psi in the protein structure were used as 
a measure of its confirmation. The Ramachandran plot predicts the 
confirmation and stability of a protein in terms of allowed and 
disallowed region. 
Dataset preparation 
A quantitative structure active relationship study is generally 
carried to predict the biological activity of unknown structures using 
the known biological activity structurally similar scaffolds. Biological 
activity is generally defined in terms of half minimal inhibitory 
concentration (IC50) and inhibitory constant (kI). Since no studies 
have been done previously to evaluate the biological activity of 
Erythrinine and hence prior IC50’s did not exist for the same. Hence, 
the inhibitory constant of 10 Erythrinine analogues obtained by 
multiple molecular docking analyses was used to predict the 
biological activity of 20 newly designed compounds.  
Active site prediction 
The active site of the target protein was predicted using FT site 
server. The server uses multiple molecular probes to determine the 
active sites of the protein. 
Molecular docking analysis 
Molecular docking analysis was carried out using Autodock 4.2 from 
the Scripps research institute, USA. The target was prepared prior to 
docking analysis. Polar hydrogen atoms were added to the protein. 
The deletion of the both water molecule and inorganic charges were 
done to avoid error. Gasteiger charges were computed and added to 
the macromolecule. Lamarckian Genetic Algorithm was applied for 
ligand docking. The grid size was set to 54, 48 and 62 along the X-, Y-
and Z-axis to recognize the binding site. Spacing was set as 0.381Ε. 
The lowest binding energy conformers were selected out of 20 
different conformers for each docking simulation and resultant data 
was further analyzed. Other miscellaneous parameters were 
assigned to the default values obtained from the AutoDock 4.2 
program. Ligands were similarly prepared followed by detection of 
torsion root. Predicted active site residues were used for grid 
generation using the Autogrid program. Docking analysis was used 
to yield inhibitory constants.  
Quantitative structure activity relationship 
Multiple linear regression analyses were used to develop logistic 
QSAR models. 3D-QSAR model was built by Multiple Linear 
Regression (MLR) Method. The compounds were divided into 
training set and validation set. The training set compounds were 
used for 3D-QSAR model building using SPSS statistics version 17.0. 
Various MLR models were built and the model with a best 
correlation coefficient (r2
The total amino acids in the protein were 420 out of which 419 
(99.8%) were in allowed region and 404 (96.2%) residues were in 
favored region (98%) as determined Molprobity analysis. The 
glutamine residue at position 101 was found to be an outlier. The 
Ramachandran Plot is as shown in fig. 4. 
 
) was used for predicting the biological 
activity of designed compounds.  
RESULTS 
The chemical structures of Erythrinine and Cytisine are shown in fig. 1.  
Protein confirmation and stability 
 
Fig. 1: Structure of erythrinine and cytosine 
 
3D QSAR model 
The biological activity of a molecule is a function of its structure and 
physicochemical properties. These compounds were divided into 
training set and validation set. 3D-QSAR was performed with the 
training set by Multiple Linear Regression Analysis. Thus, pKI of 10 
compounds with 298 descriptors were subjected to MLR analysis. 4 
models were built by stepwise MLR with a median correlation 
coefficient of 0.68 (Q1-Q8 0.38-0.76). The model with r2 value of 
0.96 consisting of four was selected for prediction of biological 





Fig. 2: Scatter plot for predicted vs observed pKI values. A 
correlation coefficient of (r2
The Ligand Interaction Map of Erythrinine and Cytisine are shown in 
fig. 4. The oxygen atom in Erythrinine interacts with GLU101 
through backbone electron donation whereas the hydroxyl group 
interacts with ILE125 by acting as a side chain acceptor. In contrast, 
Glu101 was found to interact with the hydrogen atom in Cytisine 
through backbone electron donation. 
) 0.95 was observed suggestive of a 
model good quality 
 
Molecular docking analysis 
Both Erythrinine and Cytisine were individually docked to the 
predefined active site of human nicotinic acetylcholinergic receptor. 
The results of molecular docking analysis are shown in table 1. 
Results of multiple molecular docking analyses were used for 
logistic regression model building; however they are not shown 
here, considering space constraints. 
The structure of the Erythrinine and Cytisine are showed in fig. 1. 
The docking activity of the Erythrinine docked to the active site of 
human nAchR and Cytisine docked to the active site of human nAchR 
were compared in the fig. 3. Conformation of Erythrinine Bound to 
nAchR–Interactions and Cytisine Bound to nAchR are shown in 
Yellow Lines for better understanding. 
Muthukumar et al. 
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Table 1: Molecular docking analysis of erythrinine and cytisine with the human nicotinic acetylcholinergic receptor 


















Erythrinine -7.13 5.95 -7.73 0.13 0.6 0.13 1 ILE 125 -7.48 





Erythrinine docked to the active site of human nAchR Cytisine docked to the active site of human nAchR 
  
Conformation of erythrinine bound to nAchR–interactions are 
shown in yellow lines 
Conformation of cytisine bound to nAchR–interactions are shown 
in yellow lines 
Fig. 3: Erythrinine and Cytisine Docked to active site and Its interaction to nAchR 
Table 2: Predicted biological activity of erythrinine analogues 
Compounds Predicted Pki Peoe_Vsa_Hyd Smr_Vsa0 Bcut_Smr_1 Q_Vsa_Fpneg 
com_1 1.285306264 296.89053 67.861771 -0.1942066 0 
com_2 3.685077455 254.19179 80.724098 -0.24839555 0 
com_3 0.109832414 284.7399 56.861881 -0.20211932 0 
com_4 0.25954891 274.57578 56.861881 -0.20726052 0 
com_5 0.417220912 259.65903 56.861881 -0.20330851 0 
com_6 0.086956672 285.73563 56.861881 -0.20009468 0 
com_7 -0.049114907 297.81662 56.861881 -0.2017438 0 
com_8 -0.09150026 301.18179 56.861881 -0.20137261 0 
com_9 3.40339969 271.42981 80.724098 -0.23453201 0 
com_10 4.333036209 291.9856 91.723984 -0.19975716 0 
com_11 -0.196280385 302.01337 56.861881 -0.18380708 0 
com_12 -0.292741211 310.96136 56.861881 -0.18582951 0 
com_13 0.282951285 284.35535 56.861881 -0.23334116 0 
com_14 3.622315183 263.97134 80.724098 -0.25851086 0 
com_15 0.598474259 306.6701 67.861771 -0.088689245 0 
com_16 4.14023541 301.76517 91.723984 -0.18577792 0 
com_17 3.358855075 281.20938 80.724098 -0.24802288 0 
com_18 5.865277294 295.54553 105.03357 -0.18578117 0 
com_19 1.484381485 259.54086 63.947495 -0.23027033 0.052016817 
com_20 0.7894896 279.39166 56.861881 -0.31616014 0 
Compound 12, 11, 8 and 7 were found to be highly active with inhibitory constants in the range of nanomolar concentrations.  
 
  
Ligand Interaction Map–Erythrinine Ligand Interaction Map Cytisine 
Fig. 4: Ligand interaction map of erythrinine and cytosine 
Muthukumar et al. 




Fig. 5: Molprobity Ramachandran analysis of 4UXU 
 
DISCUSSION 
A Classical quantitative structure-activity relationship study has to 
primary objectives: Development of common pharmacophore and 
prediction of the biological activity of unknown from the known. 
Therefore, retrieval of half minimal inhibitory concentrations 
(IC50) is an important aspect of setting dependent variables for a 
QSAR model. However, as far as smoking cessation is concerned, 
much extensive studies have not been carried out prior and hence, 
IC50 values are not available. Another important measure of 
biological activity is the inhibitory constant. It can be calculated 
using computational systems from the binding entropy of the 
system. Autodock 4.2 uses an empirical formula to calculate the 
inhibitory constant of small molecules against macromolecular 
targets. We exploited this phenomenon to build a biological 
activity model, not the conventional structure-activity relationship 
one, but a structure-affinity relationship one. i. e a multiple 
regression model was built with inhibitory constants derived from 
multiple docking analyses in place of half minimal inhibitory 
concentrations.  
Ramachandran plot 
Peptide bonds in a protein are incapable of rotation because of 
carbon-carbon double bonds. Hence, the other two bonds in the 
main chain are capable of rotation to provide a flexible planar 
confirmation. These bonds are called as phi and psi dihedral bonds. 
A Ramachandran plot measures the dihedral angles and defines 
them in terms of spatial geometries of allowed and favored regions 
as no two residues cannot spatially occupy in the same position. The 
total amino acids in the protein were 420 out of which 419 (99.8%) 
were in allowed region and 404 (96.2%) residues were in favored 
region (98%) as determined Molprobity analysis. The glutamine 
residue at position 101 was found to be an outlier. (fig. 5) 
Molecular docking analyses 
Autodock analyzes the interactions of small molecules with active 
sites of large peptide assemblies in terms of binding energy (ΔG), 
hydrogen bonding interactions, π-π interactions, and ligand 
conformation within the active site and root means square deviation 
(RMSD) of the active site residues. The free energy of binding is 
calculated using the empirical formula, 
Binding energy (ΔG) = Intermolecular energy+Vanderwaal’s 
hydrogen bond desolvation energy+Electrostatic energy+Total 
internal energy+Torsional energy–Unbound energy of the system. 
The similarity of docked structures is measured by computing the 
root mean square deviation and clusters are created based on the 
comparison of conformations and estimated RMSD values. 
Muthukumar et al. 
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It was observed that oxygen atom in Erythrinine interacts with 
GLU101 through backbone electron donation whereas the hydroxyl 
group interacts with ILE125 by acting as a side chain acceptor. In 
contrast, Glu101 was found to interact with the hydrogen atom in 
Cytisine through backbone electron donation. 
Cytisine was superior to nicotine-replacement therapy for smoking 
cessation among dependent 
Smokers motivated to quit [17]. A quantitative structure-affinity 
relationship model with a strong correlation coefficient of 0.96 
endorses that Erythrinine having a strong affinity with α4β2 nACh 
receptors as Cytisine it shows that Erythrinine is an effective 
smoking-cessation aid for use as a first-line treatment for tobacco 
dependence Hence the comparative study concluded that 
Erythrinine, derivatives of Erythrina and its analogues alkaloids may 
use as antismoking agent. 
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